HK Stock Market Move | INSILICO (03696) rose over 10% after announcing a formal R&D collaboration with Yuanma Zhiyao to strategically advance the next-generation mRNA cancer vaccine.

INSILICO (03696) rose over 10%, and as of the time of publication, it increased by 10.5% to HKD 43.62, with a trading volume of HKD 1.544 billion. In terms of news, on August 20, according to INSILICO's official WeChat account, the company announced today the establishment of a research and development collaboration with Byterna Therapeutics, which focuses on next-generation RNA innovative drug development. The two parties will collaborate on AI-driven new antigen prediction and sequence design, circular mRNA, targeted delivery, automated experiments, and smart manufacturing to jointly build a next-generation mRNA AI-native R&D engine, exploring personalized tumor vaccines and related innovative therapies. INSILICO and Byterna Therapeutics will differentiate their focus on circular mRNA. Compared to traditional linear mRNA, circular mRNA has research potential in molecular stability and sustained expression due to its closed-loop structure. Byterna Therapeutics has established a technical accumulation around circular mRNA molecular design, cyclization engineering, chemical modification, tLNP targeted delivery, production purification, and CMC, aiming to enhance developability and make the risks of innate immune activation more controllable.